Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hygieia
More Antibodies Than Stars: Overhauling Antibody Drug Discovery
Antiverse co-founder and CEO Murat Tunaboylu, one of In Vivo’s 2022 Rising Leaders, on defining success and why software engineers should consider a career transition to life sciences.
Execs On The Move, October 2015
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Medtech Execs On The Move, October 2015
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Glaucoma Devices: Progress On Multiple Fronts
Recent progress on the US regulatory front is generating renewed interest in device-based glaucoma therapies, which potentially could grow to a multibillion-dollar industry. The list of companies targeting this space continues to expand, as does the variety of potential device-based solutions: the current pipeline includes several innovative and less invasive products and technologies designed to improve surgical outcomes, a growing number of advanced drug-delivery inserts to address the patient noncompliance issue that is so common in this arena, and some unique patient monitoring devices.
- Digital Health
- Medical Devices
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Glucose Testing
- Other Names / Subsidiaries
- Hygieia Research, LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.